BioMarin agreed to acquire Alesta Therapeutics BV’s lead oral small-molecule candidate ALE-1 in a transaction valued at $275 million upfront and up to $490 million with milestones. The asset targets mineralization biology for hypophosphatasia, reinforcing BioMarin’s strategy in skeletal disease rather than expanding into unrelated therapeutic areas. ALE-1 is in phase I/IIa for hypophosphatasia and is positioned as an oral option in a space that has increasingly valued convenience and scalable dosing. Analysts described the deal as consistent with BioMarin’s continued interest in the inorganic pyrophosphate (PPi) pathway. The acquisition follows BioMarin’s earlier decision to discontinue BMN-401 (INZ-701), which also targeted the PPi axis, highlighting how companies recycle platform hypotheses but can alter programs based on emerging clinical or development signals.